Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Lev Gerlovin
Evolving Business Models: Pharmaceutical Incubators
By Lev Gerlovin, Jared Levine, Suneil Mendiratta As pharmaceutical manufacturers grow, they often pursue external sources of innovation to supplement their own R&D efforts. A recent study found that 45% of drugs in the pipelines of 20 large biopharmaceutical companies were sourced externally in 2020. Sources of external innovation include M&A, university partnerships, licensing, joint ventures, and direct ownership investments.
Digital Health Technologies: The Evolving Landscape Of Reimbursement & 4 Strategies To Consider
By Eva Marchese, Lev Gerlovin, Lorenzo D’Angelo, and Anthony Barron, Life Sciences Practice, CRA The use of digital health technologies (DHTs), ranging from devices and apps to cloud-based services and artificial intelligence platforms, has accelerated rapidly in recent years, especially in response to the COVID-19 pandemic.
Harnessing The Power Of AI In MS Diagnosis, Monitoring, And Treatment
By Andrew Thomson, Logan Wright, and Lev Gerlovin, Life Sciences Practice, CRA Applications of artificial intelligence (AI) are rapidly expanding in healthcare, including the handling of administrative logistics at hospitals, assessment of patient health data, and analysis of novel molecules in drug discovery.
Harnessing The Power Of AI In MS Diagnosis, Monitoring, And Treatment
By Andrew Thomson, Logan Wright, and Lev Gerlovin, Life Sciences Practice, CRA Applications of artificial intelligence (AI) are rapidly expanding in healthcare, including the handling of administrative logistics at hospitals, assessment of patient health data, and analysis of novel molecules in drug discovery.
Harnessing The Power Of AI In MS Diagnosis, Monitoring, And Treatment
By Andrew Thomson, Logan Wright, and Lev Gerlovin, Life Sciences Practice, CRA Applications of artificial intelligence (AI) are rapidly expanding in healthcare, including the handling of administrative logistics at hospitals, assessment of patient health data, and analysis of novel molecules in drug discovery.
Three Key Hurdles Restraining the Growth of the Tissue Engineering Field
The interdisciplinary field of regenerative medicine – comprised of tissue engineering (TE), cell therapy (CT), and gene therapy (GT) – is growing rapidly, characterized by groundbreaking therapeutic advances that have the potential to change how healthcare providers deliver care.
Understanding the Three Major Challenges Limiting Innovation In Tissue Engineering
By Lev Gerlovin, Andrew Thomson, and Jack Vailas, Life Sciences Practice, CRA The regenerative medicine sector, comprised of tissue engineered products and cell and gene therapies, has grown rapidly over the past decade, including significant therapeutic advances that offer the prospect of optimizing and transforming patient care.
How pharma companies are shifting deal strategies for cell and gene therapies
Lev Gerlovin, vice president in the Life Sciences Practice at Charles River Associates (CRA), and Pascale Diesel former vice president in the Life Sciences Practice at CRA, discuss how pharma companies are changing their strategies when it comes to cell and gene therapies. In recent years, drug development has been transitioning from a “one pill fits all” approach to a focus on more targeted and personalised therapies, including many cell and gene therapies.
03.04.20 -- The 10 Phases Of An Effective CAPA
Sponsor Biologic API Contract Manufacturer Quality Benchmarking (5th Edition) This report provides pharmaceutical companies and contract manufacturers with a comprehensive analysis of current outsourcing trends and practices, in addition to a quantitative analysis of CMO service quality across a series of 22 performance attributes specific to outsourced drug substance manufacturing.
3D Bioprinting: Clearing the Hurdles - BioProcess International
Bioprinted organs soon could revolutionize clinical trials, transplantation, and regenerative medicine. But as Chris Lo reminds us in a new GlobalData report (1), several technical hurdles must be negotiated before biopharmaceutical companies can harness three-dimensional (3D) bioprinting for such purposes.
Cell Gene Therapy Deals Emerging Trends To Watch
By Lev Gerlovin and Pascale Diesel The pace of deal-making in cell and gene therapy is faster and occurring much earlier in the drug development process compared to what has historically been seen for other innovative therapies.
Cell Gene Therapy Deals Emerging Trends To Watch
By Lev Gerlovin and Pascale Diesel The pace of deal-making in cell and gene therapy is faster and occurring much earlier in the drug development process compared to what has historically been seen for other innovative therapies.
Bioprinting Capabilities and Futures - BioProcess International
Figure 1: Major hurdles facing the bioprinting field; findings based on primary and secondary research by Charles River Associates (CRA). Bioprinting has advanced rapidly through engineering step changes in the use of three-dimensional (3D) printing. With these developments, living cells can be positioned layer by layer to produce functional tissue structures.
Bioprinting: The key development hurdles to scalability
Pascale Diesel and Lev Gerlovin, both vice presidents at Charles River Associates (CRA), describe the current capabilities and future potential of bioprinting alongside Andrew Thomson, an analyst in the life sciences practice at CRA. Bioprinting has advanced rapidly over recent years through engineering step-changes in the use of 3D printing devices. With these developments, living cells can now be positioned layer-by-layer to produce functional tissue structures.
4 Emerging Commercialization Strategies For Gene And Cell Therapies
Progress in development of gene and cell therapies around the world has potential to transform standards of care for a range of diseases and address significant areas of unmet need in healthcare over the coming years. In the U.S. alone, almost 20 gene and cell therapy products have been approved thus far,1 with many other development programs reaching later clinical stages.
Building New Business Models To Support Cell And Gene Therapy RD
Building New Business Models To Support Cell And Gene Therapy R&D Source: Life Science Leader The global focus on gene and cell therapies has grown exponentially in recent years as more development programs have advanced to later stages or even approval. There are now clinical stage development programs in gene therapy targeting almost 50 different diseases, up from 10 only a few years ago.
Building New Business Models To Support Cell And Gene Therapy RD
Building New Business Models To Support Cell And Gene Therapy R&D Source: Life Science Leader The global focus on gene and cell therapies has grown exponentially in recent years as more development programs have advanced to later stages or even approval. There are now clinical stage development programs in gene therapy targeting almost 50 different diseases, up from 10 only a few years ago.
Building new business models to support high-cost cell and gene therapies
Lev Gerlovin (pictured left) and Walter Colasante are vice presidents at the life sciences division of… To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Lev
Contact Lev, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack